



Innovating for  
affordable healthcare

# Shilpa Medicare Limited

**Manufacturers and Exporters of Bulk Drugs**

Shilpa House # 12-6-214/A-1, Hyderabad Road,  
RAICHUR - 584 135, Karnataka, India.

Phone : +91-8532-238704, Fax : +91-8532-238876

E-mail : [info@vbshilpa.com](mailto:info@vbshilpa.com) Website : <http://www.vbshilpa.com>

CIN No. L85110KA1987PLC008739

01<sup>st</sup> January 2019

Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**MUMBAI-400 051**

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI (LODR) Regulations- Reg.  
Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

\*\*\*\*\*

This is to inform you that the Company has received U.S. Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) Single Dose Vials.

Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum.

According to IQVIA MAT Q2 2018 data, the US market for Irinotecan HCL approximately USD 18 million.

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**

  
**MADHUSUDHAN REDDY**  
Company Secretary &  
Compliance Officer

